# A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer

Source: https://onco.cc/trials/nct05077449/  
OnCo record `nct05077449` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing XZP-3287 in HR-positive / HER2-negative breast cancer, active and no longer recruiting.

## Summary

A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer is a phase 3 interventional study registered as NCT05077449, led by Xuanzhu Biopharmaceutical, and active but no longer recruiting on the registry. Official title: A Phase III Study to Evaluate the Efficacy and Safety of XZP-3287 in Combination With Fulvestrant Versus Placebo Combined With Fulvestrant in Patients With HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer. Planned enrolment is 300 participants (estimated). The study started in 2021-11-16 and primary completion is expected in 2024-02-22. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT05077449
- Phase: 3
- Setting: A Phase III Study to Evaluate the Efficacy and Safety of XZP-3287 in Combination With Fulvestrant Versus Placebo Combined With Fulvestrant in Patients With HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer
- Sponsor: Xuanzhu Biopharmaceutical
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT05077449: https://clinicaltrials.gov/study/NCT05077449

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- drugs: [XZP-3287](https://onco.cc/drugs/xzp-3287/)
- companies: [Xuanzhu Biopharmaceutical](https://onco.cc/companies/xuanzhu-biopharmaceutical/)
- key papers: [Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis](https://onco.cc/key-papers/paper-nct05077449-nat-commun-2025/)

---
JSON: https://onco.cc/api/v1/entities/nct05077449.json